Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Lung Cancer

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0169-5002(99)00107-5PMID 10704706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GD3 expression by cultured human tumor cells of neuroectodermal origin

  2004cited by this paper
• Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.

  1999cited by this paper
• Ganglioside vaccines with emphasis on GM2.

  1998cited by this paper
• 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

  1998cited by this paper
• Anti‐melanoma effects of R24, a monoclonal antibody against GD3 ganglioside

  1997cited by this paper
• Small cell lung cancer: state-of-the-art therapy in 1996.

  1997cited by this paper
• Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

  1996cited by this paper
• Small Cell Lung Cancer: State-of-the-Art Therapy 1994

  1995cited by this paper
• Structure and function of sphingoglycolipids in transmembrane signalling and cell-cell interactions.

  1993cited by this paper
• Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer.

  1992cited by this paper
• Immunohistochemical detection of two small cell lung carcinoma‐associated antigens defined by MAbs F12 and 123C3 in bronchoscopy biopsy tissues

  1991cited by this paper
• Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies.

  1989cited by this paper
• Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.

  1989cited by this paper
• Binding specificity of monoclonal antibodies to ganglioside, Fuc-GM1.

  1986cited by this paper
• Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.

  1986cited by this paper
• Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1.

  1986cited by this paper
• Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

  1985cited by this paper
• GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody

  1982cited by this paper
• Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

  1982cited by this paper
• The nomenclature of lipids. IUPAC-IUB Commission on Biochemical Nomenclature (CBN).

  1970cited by this paper

• Tumor-associated carbohydrate antigens: Biomarker discovery and clinical application.

  2025cites this paper
• Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles

  2025cites this paper
• SC134-TCB Targeting Fucosyl-GM1, a T Cell–Engaging Antibody with Potent Antitumor Activity in Preclinical Small Cell Lung Cancer Models

  2024cites this paper
• Current state and upcoming opportunities for immunoPET biomarkers in lung cancer.

  2022cites this paper
• Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy

  2021cites this paper
• A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer

  2018cites this paper
• Challenges for the development of immunotherapy in small-cell lung cancer

  2018cites this paper
• Small Cell Lung cancer: Molecular Oncology Approach

  2017cites this paper
• Tumor Associated Carbohydrate Antigens in Targeted Therapy

  2016cites this paper
• Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study.

  2016cites this paper
• Immune Therapy.

  2016cites this paper
• The metabolomic detection of lung cancer biomarkers in sputum.

  2016cites this paper
• Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study

  2016cites this paper
• Personalized Therapy of Small Cell Lung Cancer.

  2016cites this paper
• Novel therapies in small cell lung cancer.

  2015cites this paper
• Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation

  2014cites this paper
• Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

  2014cites this paper
• Efficacy of chemotherapy in limited-disease small-cell lung cancer

  2013cites this paper
• Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

  2013cites this paper
• Novel therapeutic approaches for small cell lung cancer: the future has arrived.

  2012influential citation
• Gangliosides as Therapeutic Targets for Cancer

  2012cites this paper
• Novel Therapies for the Treatment of Small-Cell Lung Cancer

  2012cites this paper
• Immunological Approaches to the Treatment of Lung Cancer

  2010cites this paper
• The molecular pathogenesis of small cell lung cancer

  2010cites this paper
• 小细胞肺癌的的分子发病机制

  2010cites this paper
• Current vaccine updates for lung cancer

  2010cites this paper
• Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors

  2010cites this paper
• 6.04 – Carbohydrate Vaccines

  2010cites this paper
• Vaccine Therapy for Lung Cancer

  2010cites this paper
• Current clinical management of metastatic lung cancer

  2009cites this paper
• Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

  2009cites this paper
• Current status of clinical trials for small cell lung cancer.

  2008cites this paper
• Unmet need in lung cancer: can vaccines bridge the gap?

  2008cites this paper
• Glycobiology and Immunology

  2008cites this paper
• Targeted therapies in small-cell lung cancer

  2007influential citation
• Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.

  2007cites this paper
• Lung cancer vaccines.

  2007cites this paper
• Synthetic Glycopeptide-Based Vaccines

  2006cites this paper
• Genetic mechanisms for the synthesis of fucosyl GM1 in small cell lung cancer cell lines.

  2006cites this paper
• Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

  2005cites this paper
• Carbohydrate vaccines as immunotherapy for cancer

  2005cites this paper
• Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

  2005cites this paper
• Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin

  2004cites this paper
• Gangliosides act as onconeural antigens in paraneoplastic neuropathies.

  2004cites this paper
• Correlation of gangliosides GM2 and GM3 with metastatic potential to lungs of mouse B16 melanoma.

  2003cites this paper
• Ganglioside GD 2 in Small Cell Lung Cancer Cell Lines : Enhancement of Cell Proliferation and Mediation of Apoptosis 1

  2001cites this paper
• Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis.

  2001cites this paper